. 2023 Aug 17;23(2):262–271. doi: 10.17998/jlc.2023.07.17

Table 1.

Summary of outcomes of key phase 3 first-line trials in advanced HCC

Trial	Comparator	Median OS (months)	PFS (months)	ORR (%)
REFLECT³	Lenvatinib vs. sorafenib (control)	13.6 vs. 12.3; HR, 0.92; 95% CI, 0.79-1.06^*	7.4 vs. 3.7; HR, 0.66; 95% CI, 0.57-0.77	18.8 vs. 6.5
SHARP²	Sorafenib vs. placebo (control)	10.7 vs. 7.9; HR, 0.69; 95% CI, 0.55-0.87	5.5 vs. 2.8; HR, 0.58; 95% CI, 0.45-0.74	18.8 vs. 6.5
IMBrave-150⁶,¹⁶	Atezolizumab plus Bevacizumab vs. sorafenib (control)	19.2 vs. 13.4; HR, 0.66; 95% CI, 0.52-0.85	6.8 vs. 4.3; HR, 0.59; 95% CI, 0.47-0.76	30 vs. 11
HIMALAYA⁸	Durvalumab plus tremelimumab vs. sorafenib (control)	16.4 vs. 13.8; HR, 0.78; 95% CI, 0.65-0.92	3.8 vs. 4.1; HR, 0.90; 95% CI, 0.77-1.05	20.1 vs. 5.1

HCC, hepatocellular carcinoma; OS, overall survival; PFS, progression-free survival; ORR, overall response rate; HR, hazard ratio; CI, confidence interval.

Non-inferiority criteria met.